StockNews.AI
OLMA
StockNews.AI
4 days

Olema Oncology to Present Preclinical Data for OP-3136, a Potent KAT6 Inhibitor, Demonstrating Anti-Tumor Activity in Multiple Solid Tumor Models at the 2025 AACR Annual Meeting

1. Olema presents OP-3136's preclinical anti-tumor activity at AACR meeting. 2. OP-3136 shows promise against prostate, ovarian, and non-small cell lung cancers. 3. FDA cleared OP-3136's IND application in December 2024; Phase 1 trial ongoing. 4. Strength in overcoming resistance signals potential for treatment enhancements. 5. Company focuses on targeted breast cancer therapies and increasing pipeline value.

5 mins saved
Full Article

FAQ

Why Bullish?

The preclinical success of OP-3136 signifies potential revenue growth and therapeutic advancement, reminiscent of past successes for biotech firms after positive trial announcements.

How important is it?

The news directly relates to prospective therapies and potential market traction for Olema, increasing investor interest and stock performance.

Why Long Term?

Positive clinical trial results could lead to FDA approvals that significantly enhance future revenues, as seen with similar biotech timelines.

Related Companies

PFEAMGNJNJ
March 25, 2025 16:31 ET  | Source: Olema Oncology SAN FRANCISCO, March 25, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced it will present a poster highlighting preclinical anti-tumor activity of OP-3136, a novel small molecule that potently and selectively inhibits lysine acetyltransferase 6 (KAT6), in prostate, ovarian, and non-small cell lung cancer models in a late-breaking session at the American Association for Cancer Research (AACR) Annual Meeting taking place April 25-30 in Chicago, Illinois. Poster Presentation Details Title: OP-3136, a selective KAT6 inhibitor, demonstrates anti-tumor activity in prostate, ovarian, and non-small cell lung cancer preclinical models Poster/Abstract: LB166Session: Late-Breaking Research: Tumor Biology 2Date/Time: April 28, 2025, from 9:00am-12:00pm CT / 10:00am-1:00pm ETPresenter: Dr. Gopinath S. Palanisamy, DVM, PhD Additional information can be found on the AACR Annual Meeting website. About OP-3136OP-3136 is a novel, orally available small molecule that potently and selectively inhibits lysine acetyltransferase 6 (KAT6), an epigenetic target that is dysregulated in breast and other cancers. In preclinical studies, OP-3136 has demonstrated significant anti-proliferative activity in ER+ breast cancer models and is combinable and synergistic with endocrine therapies, including palazestrant and cyclin-dependent kinase 4/6 (CDK4/6) inhibitors. The Investigational New Drug (IND) application for OP-3136 was cleared by the U.S. Food and Drug Administration (FDA) in December 2024 and patients are currently enrolling in the Phase 1 clinical trial. About Olema OncologyOlema Oncology is a clinical-stage biopharmaceutical company committed to transforming the standard of care and improving outcomes for patients living with breast cancer and beyond. Olema is advancing a pipeline of novel therapies by leveraging our deep understanding of endocrine-driven cancers, nuclear receptors, and mechanisms of acquired resistance. Our lead product candidate, palazestrant (OP-1250), is a proprietary, orally available complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD), currently in a Phase 3 clinical trial called OPERA-01. In addition, Olema is developing OP-3136, a potent lysine acetyltransferase 6 (KAT6) inhibitor, now in a Phase 1 clinical trial. Olema is headquartered in San Francisco and has operations in Cambridge, Massachusetts. For more information, please visit www.olema.com. Media and Investor Relations ContactCourtney O’KonekVice President, Corporate CommunicationsOlema Oncologymedia@olema.com

Related News